Editorial: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban or the combination: Secondary analysis of the <scp>COMPASS</scp> randomised controlled trial-Reference-Cited by-同舟云学术

Editorial: Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban or the combination: Secondary analysis of the COMPASS randomised controlled trial

Published:2024-09-02 Issue:7 Volume:60 Page:961-962
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Sehgal Kanika¹,Shung Dennis L.²³^ORCID

Affiliation:

1. Department of Internal Medicine Yale School of Medicine New Haven Connecticut USA

2. Department of Medicine, Section of Digestive Diseases Yale School of Medicine New Haven Connecticut USA

3. Department of Biomedical Informatics and Data Science Yale School of Medicine New Haven Connecticut USA

Abstract

LINKED CONTENTThis article is linked to Forbes et al paper. To view this article, visit https://doi.org/10.1111/apt.18139

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18195

Reference6 articles.

1. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

2. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial

3. Risk of Gastrointestinal Bleeding Increases With Combinations of Antithrombotic Agents and Patient Age

4. Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: secondary analysis of the COMPASS randomised controlled trial;Forbes N;Aliment Pharmacol Ther,2024

5. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease